StockData
Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc (RIGL) income statement

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$42.53−0.39 (-0.91%)

Close on Nov 18, 2026Market cap $794.46MP/E 2.7Yield –

Rigel Pharmaceuticals Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
91.4%
Operating margin
31.5%
Net margin
116.3%
Return on equity, FY2025
185.9%

Financial strength

Current ratio
1.94
Debt to equity
–
Debt to assets
–
Cash to current liabilities
63.6%

Valuation

P/E ratio
2.7
Price to sales
2.87
Price to book
1.87
Dividend yield
–

See a number that looks wrong?